Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 36Gastrointestinal 26Thoracic 10Dermatologic 10Breast 10Tumor-Agnostic 6Lymphoid 5Head & Neck 5Gynecologic 5Endocrine 4Sarcoma 3NET 3Other solid neoplasm 2CNS 2Plasma cell 1

Conditions

Neuroendocrine Tumors 3Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma, Merkel Cell 1

Interventions

lutetium Lu 177 dotatate 18Everolimus 13Temozolomide 12Nivolumab 10pembrolizumab 9cabozantinib 8Capecitabine 8Sunitinib 7lenvatinib 5Magnetic Resonance Spectroscopy 5Etoposide 5lanreotide 4gallium Ga 68 dotatate 4Specimen Handling 4Ipilimumab 4Cisplatin 4Carboplatin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4telotristat ethyl 3surufatinib 3pazopanib 3avelumab 3Octreotide 3Injections 3Fluorodeoxyglucose F18 3Cyclophosphamide 3Bevacizumab 3sintilimab 2fosbretabulin 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × avelumab × NET × Clear all
NCT04291885 2026-04-09

I-MAT

Melanoma and Skin Cancer Trials Limited

Phase 2 Active not recruiting
122 enrolled
DermatologicEndocrineNET

Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT03278379 2024-12-24

NET-002

Sunnybrook Health Sciences Centre

Phase 2 Completed
17 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03352934 2022-02-25

AveNEC

Johannes Gutenberg University Mainz

Phase 2 Completed
60 enrolled
EndocrineNET

Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡